CPRX
Catalyst Pharmaceuticals Inc. Healthcare - Pharmaceuticals Investor Relations →
Catalyst Pharmaceuticals Inc. (CPRX) closed at $28.74 as of 2026-05-01, trading 58.5% above its 200-week moving average of $18.13. The stock moved further from the line this week, up from 51.9% last week. With a 14-week RSI of 74, CPRX is in overbought territory.
A big jump in activity this week — 2.6x the usual volume, and the price went up. Significantly more people than usual decided to buy. This kind of surge, especially on a stock already below its 200-week average, can be an early sign that sentiment is shifting.
Over the past 968 weeks of data, CPRX has crossed below its 200-week moving average 9 times. On average, these episodes lasted 42 weeks. Historically, investors who bought CPRX at the start of these episodes saw an average one-year return of +66.5%.
With a market cap of $3.5 billion, CPRX is a mid-cap stock. The company generates a free cash flow yield of 4.9%. Return on equity stands at 25.5%, indicating strong profitability. The stock trades at 3.7x book value.
Share count has increased 16.4% over three years, indicating dilution. CPRX passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 18.6 years, a hypothetical investment of $100 in CPRX would have grown to $884, compared to $654 for the S&P 500. That represents an annualized return of 12.4% vs 10.6% for the index — confirming CPRX as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CPRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CPRX Crosses Below the Line?
Across 9 historical episodes, buying CPRX when it crossed below its 200-week moving average produced an average return of +62.3% after 12 months (median +83.0%), compared to +11.9% for the S&P 500 over the same periods. 67% of those episodes were profitable after one year. After 24 months, the average return was +168.9% vs +15.9% for the index.
Each line shows $100 invested at the moment CPRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CPRX has crossed below its 200-week MA 9 times with an average 1-year return of +66.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 2007 | Aug 2008 | 44 | 38.1% | -12.1% | +818.2% |
| Sep 2008 | Jul 2012 | 202 | 87.0% | -64.9% | +833.1% |
| Nov 2012 | Jul 2013 | 35 | 63.2% | +227.3% | +6431.8% |
| Jan 2016 | May 2017 | 73 | 73.9% | -38.9% | +1412.6% |
| Mar 2018 | Apr 2018 | 2 | 4.5% | +113.4% | +1102.5% |
| Nov 2018 | Jan 2019 | 6 | 21.5% | +82.7% | +1031.5% |
| Aug 2020 | Nov 2020 | 13 | 13.4% | +64.8% | +765.7% |
| Dec 2020 | Jan 2021 | 4 | 5.5% | +109.9% | +740.4% |
| Mar 2021 | Mar 2021 | 1 | 2.8% | +116.1% | +714.2% |
| Average | 42 | — | +66.5% | — |
Frequently Asked Questions
Is CPRX below its 200-week moving average?
No. Catalyst Pharmaceuticals Inc. (CPRX) is currently 58.5% above its 200-week moving average of $18.13. It would need to fall to $18.13 to cross below the line.
What is CPRX's 200-week moving average price?
Catalyst Pharmaceuticals Inc.'s 200-week moving average is $18.13 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CPRX drops below its 200-week moving average?
CPRX has crossed below its 200-week moving average 9 times in our data. On average, buying at that moment produced a one-year return of +66.5%. These dips have historically been decent entry points. These episodes lasted 42 weeks on average.
Is CPRX a good value right now?
Here's what our data says about CPRX as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 74 (overbought). Free cash flow yield is 4.9%. Return on equity is 25.5%. Price-to-book is 3.7x. This is not a buy or sell recommendation — always do your own research.
How does CPRX compare to the S&P 500?
Over the past 18.6 years, $100 invested in CPRX would have grown to $884, compared to $654 for the S&P 500. That's 12.4% annualized vs 10.6% for the index. CPRX has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01